NeuroPace (NPCE) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)
NeuroPace (NPCE) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | 17.54% |
| 10 | NeuroPace | 470.30 Mn | 418.60 Mn | 18.91 Mn | 12.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.97% |
| Dec 31, 2025 | 38.25% |
| Sep 30, 2025 | 24.71% |
| Jun 30, 2025 | -20.33% |
| Mar 31, 2025 | 16.99% |
| Dec 31, 2024 | 11.36% |
| Sep 30, 2024 | 10.49% |
| Jun 30, 2024 | -6.33% |
| Mar 31, 2024 | -16.54% |
| Dec 31, 2023 | 62.93% |
| Sep 30, 2023 | -23.04% |
| Jun 30, 2023 | -8.40% |
| Mar 31, 2023 | -4.17% |